ArticleAlzheimer's & dementia (New York, N. Y.)2018
Statistical advances in clinical trials and clinical research.
Article in Alzheimer's & dementia (New York, N. Y.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Disease progression trajectory curves to estimate saved time in Alzheimer's disease trials.Contemporary clinical trials · 2025Article
- Blood biomarkers as surrogate endpoints in Alzheimer's disease research.Frontiers in aging neuroscience · 2025Article
- Comparison of Pocock and Simon's covariate-adaptive randomization procedures in clinical trials.BMC medical research methodology · 2024Article
- ADSS: A Composite Score to Detect Disease Progression in Alzheimer's Disease.Journal of Alzheimer's disease reports · 2024Article
- Effects of dose change on the success of clinical trials.Contemporary clinical trials communications · 2022Article
- Monte Carlo cross-validation for a study with binary outcome and limited sample size.BMC medical informatics and decision making · 2022Article
- Randomized two-stage optimal design for interval-censored data.Journal of biopharmaceutical statistics · 2022Article
- Optimal two-stage designs based on restricted mean survival time for a single-arm study.Contemporary clinical trials communications · 2021Article
- Machine learning methods to predict amyloid positivity using domain scores from cognitive tests.Scientific reports · 2021Article
- Partial correlation coefficient for a study with repeated measurements.Statistics in biopharmaceutical research · 2021Article
- Alzheimer's Disease, and Breast and Prostate Cancer Research: Translational Failures and the Importance to Monitor Outputs and Impact of Funded Research.Animals : an open access journal from MDPI · 2020Review
- Accurate confidence intervals for risk difference in meta-analysis with rare events.BMC medical research methodology · 2020Article
- Correlation Coefficients for a Study with Repeated Measures.Computational and mathematical methods in medicine · 2020Article
- Two-stage optimal designs with survival endpoint when the follow-up time is restricted.BMC medical research methodology · 2019Article
- Alzheimer's disease drug development pipeline: 2019.Alzheimer's & dementia (New York, N. Y.) · 2019Article
- Comparison between treatment-placebo difference and saved time measures to assess treatment effect in Alzheimer's disease.Journal of Alzheimer's disease reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionNew treatments for neurodegenerative disease are urgently needed, and clinical trial methods are an essential component of new drug development. Although a parallel-group study design for neurological disorder clinical trials is commonly used to test the effectiveness of a new treatment as compared to placebo, it does not efficiently use information from the on-going study to increase the success rate of a trial or to stop a trial earlier when the new treatment is indeed ineffective.
methodsWe review some recent advances in designs for clinical trials, including futility designs and adaptive designs.
resultsFutility designs and noninferiority designs are used to test the nonsuperiority and the noninferiority of a new treatment, respectively. We provide some guidance on using these two designs and analyzing data from these studies properly. Adaptive designs are increasingly used in clinical trials to improve the flexibility and efficiency of trials with the potential to reduce resources, time, and costs. We review some typical adaptive designs and new statistical methods to handle the statistical challenges from adaptive designs. DISCUSSION: Statistical advances in clinical trial designs may be helpful to shorten study length and benefit more patients being treated with a better treatment during the discovery of new therapies for neurological disorders. Advancing statistical underpinnings of neuroscience research is a critical aspect of the core activities supported by the Center of Biomedical Research Excellence award supporting the Center for Neurodegeneration and Translational Neuroscience.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.